Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRF | P10586 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 16/20 | 0.42 |
| ▸ | PPARG | P37231 | 15/20 | 0.42 |
| ▸ | PPARD | Q03181 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1751479 | 0.92 | ALDH1A1 (0.35) | PTPRFPTPN2PTPN1PPARAPPARG | |
| SCHEMBL1751482 | 0.92 | ALDH1A1 (0.35) | PTPRFPTPN2PTPN1PPARAPPARG | |
| SCHEMBL1749931 | 0.92 | PPARA (0.42) | PTPRFPTPN2PTPN1PPARAPPARG | |
| SCHEMBL1749562 | 0.87 | PPARA (0.43) | PTPRFPTPN2PTPN1PPARAPPARG | |
| SCHEMBL1749604 | 0.85 | PTPRF (0.41) | PTPRFPTPN2PTPN1PPARAPPARG | |
| SCHEMBL1749603 | 0.85 | PTPRF (0.41) | PTPRFPTPN2PTPN1PPARAPPARG | |
| SCHEMBL2217322 | 0.85 | PTPRF (0.41) | PTPRFPTPN2PTPN1PPARAPPARG | |
| SCHEMBL1750019 | 0.85 | PTPRF (0.41) | PTPRFPTPN2PTPN1PPARAPPARG | |
| SCHEMBL1751060 | 0.84 | AVPR1B (0.36) | PTPRFPTPN2PTPN1PPARAPPARG | |
| SCHEMBL1751057 | 0.84 | AVPR1B (0.36) | PTPRFPTPN2PTPN1PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638964-B1 | NOVEL COMPOUNDS THAT MODULATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2011-07-27 | — | — | EP | claimed |
| US-7968560-B2 | Compounds that modulate PPARγ-type receptors and cosmetic/pharmaceutical compositions comprising said compounds | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-06-28 | — | — | US | claimed |
| US-20100247468-A1 | Compounds that modulate PPAR gamma-type receptors and cosmetic/pharmaceutical compositions comprising said compounds | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-09-30 | — | — | US | claimed |
| US-20060148862-A1 | Novel compounds that modulate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-07-06 | — | — | US | claimed |
| US-8022079-B2 | Methods of modulating PPAR gamma-type receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-09-20 | — | — | US | disclosed |
| EP-1638964-B1 | NOVEL COMPOUNDS THAT MODULATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2011-07-27 | — | — | EP | disclosed |
| US-7968560-B2 | Compounds that modulate PPARγ-type receptors and cosmetic/pharmaceutical compositions comprising said compounds | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-06-28 | — | — | US | disclosed |
| US-20100247468-A1 | Compounds that modulate PPAR gamma-type receptors and cosmetic/pharmaceutical compositions comprising said compounds | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100099689-A1 | METHODS OF MODULATING PPAR GAMMA-TYPE RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-04-22 | — | — | US | disclosed |
| US-7625914-B2 | Compounds that modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-12-01 | — | — | US | disclosed |
| US-20060148862-A1 | Novel compounds that modulate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099689-A1 | METHODS OF MODULATING PPAR GAMMA-TYPE RECEPTORS | PPARG, PPARA, PPARD | PTPRF 908/4885PTPN2 916/4885PTPN1 991/4885 |
| US-20060148862-A1 | Novel compounds that modulate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | PTPRF 1014/4885PTPN2 768/4885PTPN1 713/4885 |
| US-20100247468-A1 | Compounds that modulate PPAR gamma-type receptors and cosmetic/pharmaceutical compositions comprising said compounds | PPARG, PPARD, PPARA | PTPRF 1148/4885PTPN2 866/4885PTPN1 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.